Albert Powers, MD, PhD
Associate Professor of PsychiatryDownloadHi-Res Photo
Cards
Appointments
Psychiatry
Primary
Department of Psychology
Secondary
Additional Titles
Medical & Associate Director, Yale PRIME Psychosis Risk Clinic, Psychiatry
Contact Info
Appointments
Psychiatry
Primary
Department of Psychology
Secondary
Additional Titles
Medical & Associate Director, Yale PRIME Psychosis Risk Clinic, Psychiatry
Contact Info
Appointments
Psychiatry
Primary
Department of Psychology
Secondary
Additional Titles
Medical & Associate Director, Yale PRIME Psychosis Risk Clinic, Psychiatry
Contact Info
About
Titles
Associate Professor of Psychiatry
Medical & Associate Director, Yale PRIME Psychosis Risk Clinic, Psychiatry
Biography
Dr. Powers is an Associate Professor at the Yale University Department of Psychiatry and Medical Director and Associate Director of the PRIME Psychosis Risk Clinic at Yale. In addition to treating individuals who suffer from the symptoms of early psychosis, he uses computational approaches to understand how sensory systems might go awry to produce hallucinations and other symptoms of psychosis.
Last Updated on June 30, 2023.
Appointments
Psychiatry
Associate Professor on TermPrimaryDepartment of Psychology
Assistant ProfessorSecondary
Other Departments & Organizations
- Center for Brain & Mind Health
- Department of Psychology
- Interdepartmental Neuroscience Program
- Janeway Society
- MR Core
- Neural Disorders
- Neuroscience Research Training Program (NRTP)
- Neuroscience Track
- Powers Lab
- PRIME Psychosis Prodrome Research Clinic
- Psychiatry
- Wu Tsai Institute
- Yale Combined Program in the Biological and Biomedical Sciences (BBS)
Education & Training
- Resident
- Yale School of Medicine (2016)
- Chief Resident, Neuroscience Research Training Program
- Yale School of Medicine (2016)
- PhD
- Vanderbilt University School of Medicine (2012)
- MD
- Vanderbilt University School of Medicine (2012)
- BA
- Yale University (2004)
Research
Overview
Medical Research Interests
Behavioral Sciences; Computational Biology; Hallucinations; Patient-Specific Modeling; Psychotic Disorders; Resilience, Psychological; Risk Assessment; Schizophrenia; Stress Disorders, Traumatic
ORCID
0000-0003-3057-5043- View Lab Website
Powers Lab
Research at a Glance
Yale Co-Authors
Frequent collaborators of Albert Powers's published research.
Publications Timeline
A big-picture view of Albert Powers's research output by year.
Research Interests
Research topics Albert Powers is interested in exploring.
Scott Woods, MD
Philip Corlett, PhD
Ely Sibarium
Godfrey Pearlson, MA, MBBS
Vinod H. Srihari, MD
Zailyn Tamayo
94Publications
3,103Citations
Psychotic Disorders
Hallucinations
Schizophrenia
Risk Assessment
Publications
2025
Functional Correlates of Atypical Visuoperceptual Organization in a Multisite Clinical High-Risk Sample
Pokorny V, Tran T, Williams T, Kenney J, Silverstein S, Gold J, Waltz J, Schiffman J, Ellman L, Strauss G, Walker E, Woods S, Powers A, Corlett P, Mittal V. Functional Correlates of Atypical Visuoperceptual Organization in a Multisite Clinical High-Risk Sample. Journal Of Psychopathology And Clinical Science 2025, 134: 527-539. PMID: 40193439, PMCID: PMC12162206, DOI: 10.1037/abn0000992.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsClinical high riskPsychotic-like Experiences groupClinical high-risk statusClinical high-risk samplesMeasures of cognitive abilityClinical high-risk groupHigh-risk sampleMeasuring perceptual organizationFaces taskPsychotic disordersPerceptual priorsCognitive abilitiesCognitive functionClinical groupsPerceptual organizationHealthy control groupContext-sensitiveSocial functioningTwo-tone imagesTarget circleSymbolic codeEbbinghausFunctional correlatesTaskParticipantsThe electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures
Mathalon D, Nicholas S, Roach B, Billah T, Lavoie S, Whitford T, Hamilton H, Addamo L, Anohkin A, Bekinschtein T, Belger A, Buccilli K, Cahill J, Carrión R, Damiani S, Dzafic I, Ebdrup B, Izyurov I, Jarcho J, Jenni R, Jo A, Kerins S, Lee C, Martin E, Mayol-Troncoso R, Niznikiewicz M, Parvaz M, Pogarell O, Prieto-Montalvo J, Rabin R, Roalf D, Rogers J, Salisbury D, Shaik R, Shankman S, Stevens M, Suen Y, Swann N, Tang X, Thompson J, Tso I, Wenzel J, Zhou J, Addington J, Alameda L, Arango C, Breitborde N, Broome M, Cadenhead K, Calkins M, Castillo-Passi R, Chen E, Choi J, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Ellman L, Fusar-Poli P, Gaspar P, Gerber C, Glenthøj L, Horton L, Hui C, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim M, Kim S, Koutsouleris N, Kwon J, Langbein K, Mamah D, Mittal V, Nordentoft M, Pearlson G, Perez J, Perkins D, Powers A, Sabb F, Schiffman J, Shah J, Silverstein S, Smesny S, Stone W, Strauss G, Upthegrove R, Verma S, Wang J, Wolf D, Zhang T, Bouix S, Pasternak O, Cho K, Coleman M, Dwyer D, Nunez A, Tamayo Z, Wood S, Kahn R, Kane J, McGorry P, Bearden C, Nelson B, Woods S, Shenton M, Light G. The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures. Schizophrenia 2025, 11: 85. PMID: 40480970, PMCID: PMC12144291, DOI: 10.1038/s41537-025-00622-0.Peer-Reviewed Original ResearchAltmetricConceptsEvent-related oscillationsEEG power spectral densityClinical outcomesMarkers of illness progressionRisks of antipsychotic drugsAuditory steady state responsePredictor of clinical outcomeMismatch negativityVariable clinical outcomesControlled clinical trialsClinical high riskTest-retest reliabilitySecondary outcome measuresEEG-based measuresVisual P300Antipsychotic drugsPaired t-testEEG protocolsClinical trialsEffective medicationsInterim analysisHigh riskPersonalized treatmentTraditional frequency bandsCHR individualsDigital health technologies in the accelerating medicines Partnership® Schizophrenia Program
Wigman J, Ching A, Chung Y, Eichi H, Lane E, Langholm C, Vaidyam A, Byun A, Haidar A, Hartmann J, Nunez A, Dwyer D, Nasarudin A, Borders O, Scott I, Tamayo Z, Matneja P, Cho K, Addington J, Alameda L, Arango C, Breitborde N, Broome M, Cadenhead K, Calkins M, Chen E, Choi J, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Ellman L, Fusar-Poli P, Gaspar P, Gerber C, Glenthøj L, Horton L, Hui C, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim S, Koutsouleris N, Langbein K, Mamah D, Mathalon D, Mittal V, Nordentoft M, Pearlson G, Perez J, Perkins D, Powers A, Rogers J, Sabb F, Schiffman J, Shah J, Silverstein S, Smesny S, Yassin W, Stone W, Strauss G, Thompson J, Upthegrove R, Verma S, Wang J, Wolf D, Wolff P, Rowland L, D’Alfonso S, Pasternak O, Bouix S, McGorry P, Kahn R, Kane J, Bearden C, Woods S, Shenton M, Nelson B, Baker J, Torous J. Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program. Schizophrenia 2025, 11: 83. PMID: 40461469, PMCID: PMC12134270, DOI: 10.1038/s41537-025-00599-w.Peer-Reviewed Original ResearchAltmetricConceptsDigital componentsDigital health technologiesSmartphone-based digital phenotypingNovel digital health technologiesClinical high riskDigital phenotypingDigital dataHealth technologiesPredictive of transition to psychosisReal-life experiencesSchizophrenia ProgramDaily lifeTransition to psychosisPassive dataEpisode of psychosisPsychosis transitionMapping of experiencesTechnologyHigh riskMeta-analytic studiesCollaborative projectIncreased face perception in individuals at clinical high-risk for psychosis: mechanisms, sex differences, and clinical correlates
Tran T, Keane B, Thompson J, Robinson B, Kenney J, Williams T, Waltz J, Levin J, Kafadar E, Gold J, Schiffman J, Ellman L, Walker E, Strauss G, Mittal V, Zinbarg R, Corlett P, Powers A, Woods S, Silverstein S. Increased face perception in individuals at clinical high-risk for psychosis: mechanisms, sex differences, and clinical correlates. Schizophrenia 2025, 11: 74. PMID: 40355455, PMCID: PMC12069608, DOI: 10.1038/s41537-025-00624-y.Peer-Reviewed Original ResearchAltmetricConceptsClinical high riskCHR participantsCHR groupPhase of psychotic illnessAssessment of psychosis riskSevere positive symptomsGender of facesAssess response biasClinical correlatesPositive symptomsPsychiatric controlsPsychosis riskPsychotic illnessAccuracy of perceptionFace perceptionScrambled conditionPerceptual sensitivityPoorer roleResponse biasFace testPerceptual organizationComputerized assessmentSex differencesAltered visual perceptionPsychosis489. Mapping Phenomenology to Priors for Sound Complexity in Voice-Hearers
Dandawate A, Mourgues C, Sibarium E, Greenwald M, Powers A. 489. Mapping Phenomenology to Priors for Sound Complexity in Voice-Hearers. Biological Psychiatry 2025, 97: s299. DOI: 10.1016/j.biopsych.2025.02.727.Peer-Reviewed Original ResearchAltmetric12. Neural Signatures of Hallucination Emergence in Dementia With Lewy Bodies
Vin R, Moret S, Yi H, Lawrence M, Santini V, Cedarbaum J, Fredericks C, Powers A. 12. Neural Signatures of Hallucination Emergence in Dementia With Lewy Bodies. Biological Psychiatry 2025, 97: s100. DOI: 10.1016/j.biopsych.2025.02.249.Peer-Reviewed Original ResearchSample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program
Addington J, Liu L, Braun A, Auther A, Calkins M, Cornblatt B, Corcoran C, Fusar-Poli P, Kerr M, Mourgues-Codern C, Nunez A, Oliver D, Strauss G, Walsh B, Alameda L, Arango C, Breitborde N, Broome M, Cadenhead K, Carrion R, Chen E, Choi J, Coleman M, Conus P, Diaz-Caneja C, Dwyer D, Ellman L, Faghankhani M, Gaspar P, Gerber C, Glenthøj L, Horton L, Hui C, Jacobs G, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim S, Koutsouleris N, Kwon J, Langbein K, Lewandowski K, Mamah D, Marcy P, Mathalon D, Mittal V, Nordentoft M, Pearlson G, Penzel N, Perez J, Perkins D, Powers A, Rogers J, Sabb F, Schiffman J, Shah J, Silverstein S, Smesny S, Stone W, Thompson A, Thompson J, Upthegrove R, Verma S, Wang J, Wastler H, Wickham A, Rossum I, Wolf D, Bouix S, Pasternak O, Kahn R, Bearden C, Kane J, McGorry P, Buccilli K, Nelson B, Shenton M, Woods S, Yung A. Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program. Schizophrenia 2025, 11: 54. PMID: 40180953, PMCID: PMC11968923, DOI: 10.1038/s41537-025-00556-7.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMultisite studyClinical measuresAssessment protocolTraining of clinical staffSchizophrenia ProgramClinical ratingsClinical ascertainmentExpert clinical inputClinical assessment protocolResearch NetworkNative languageClinical outcome measuresReporting of clinical dataClinical staffSample ascertainmentClinical trainingAscertainment criteriaOutcome measuresAscertainmentClinical assessmentMeasurement teamObservational studyClinical inputCoordinating CenterSchizophreniaThe MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program
Harms M, Cho K, Anticevic A, Bolo N, Bouix S, Campbell D, Cannon T, Cecchi G, Goncalves M, Haidar A, Hughes D, Izyurov I, John O, Kapur T, Kim N, Kotler E, Kubicki M, Kuperman J, Laulette K, Lindberg U, Markiewicz C, Ning L, Poldrack R, Rathi Y, Romo P, Tamayo Z, Wannan C, Wickham A, Yassin W, Zhou J, Addington J, Alameda L, Arango C, Breitborde N, Broome M, Cadenhead K, Calkins M, Chen E, Choi J, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Ellman L, Fusar-Poli P, Gaspar P, Gerber C, Glenthøj L, Horton L, Hui C, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim S, Koutsouleris N, Kwon J, Langbein K, Mamah D, Mathalon D, Mittal V, Nordentoft M, Pearlson G, Perez J, Perkins D, Powers A, Rogers J, Sabb F, Schiffman J, Shah J, Silverstein S, Smesny S, Stone W, Strauss G, Thompson J, Upthegrove R, Verma S, Wang J, Wolf D, Kahn R, Kane J, McGorry P, Nelson B, Woods S, Shenton M, Wood S, Bearden C, Pasternak O. The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program. Schizophrenia 2025, 11: 52. PMID: 40175382, PMCID: PMC11965426, DOI: 10.1038/s41537-025-00581-6.Peer-Reviewed Original ResearchCitationsAltmetricConceptsClinical high riskSchizophrenia ProgramClinical high-risk cohortClinical high-risk stateResting-state fMRIFMRI scanningStudy of individualsNeuroimaging resultsBrain regionsNeuroimaging dataNeuroimaging protocolsStructural scansParticipation varianceDiffusion scansFMRIPercentage of participantsNeuroimagingVariance component analysisMulti-siteParticipantsPsychosisVarianceTime pointsDiffusion-weighted imagingHigh riskInterpersonal difficulties and suicidal ideation in young people at clinical high-risk for psychosis and help-seeking clinical controls
Bailey A, Bauer B, Mittal V, Ellman L, Strauss G, Walker E, Powers A, Kenney J, Corlett P, Woods S, Gold J, Schiffman J, Waltz J, Silverstein S. Interpersonal difficulties and suicidal ideation in young people at clinical high-risk for psychosis and help-seeking clinical controls. Psychiatry Research 2025, 348: 116467. PMID: 40184931, PMCID: PMC12051163, DOI: 10.1016/j.psychres.2025.116467.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsRates of suicidal ideationPresence of suicidal ideationClinical high riskSuicidal ideationInterpersonal difficultiesMental health concernsInterpersonal traumaExperiences of suicidal ideationHelp-seeking controlsDSM-5 diagnosisSame-age peersDSM-5Interpersonal mechanismsDiagnostic groupsIdeationYoung peoplePsychosisClinical controlCHRPHealth concernHigh riskAssociated with presenceDifficultiesSuicideLogistic regression modelsCognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample
Allott K, Yassin W, Alameda L, Billah T, Borders O, Buccilli K, Carrión R, Castillo-Passi R, Cho K, Chin K, Coleman M, Colton B, Corral S, Dwyer D, Gundersen K, Gur R, Hoftman G, Jacobs G, Kelly S, Lewandowski K, Marcy P, Matneja P, McLaughlin D, Nunez A, Parsa S, Penzel N, Ray S, Reinen J, Ruparel K, Sand M, Santorelli G, Seitz-Holland J, Spark J, Tamayo Z, Thompson A, Tod S, Wannan C, Wickham A, Wood S, Zoupou E, Addington J, Anticevic A, Arango C, Breitborde N, Broome M, Cadenhead K, Calkins M, Chen E, Choi J, Conus P, Corcoran C, Cornblatt B, Ellman L, Fusar-Poli P, Gaspar P, Gerber C, Glenthøj L, Horton L, Hui C, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim S, Koutsouleris N, Kwon J, Langbein K, Mamah D, Diaz-Caneja C, Mathalon D, Mittal V, Nordentoft M, Pearlson G, Perkins D, Perez J, Powers A, Rogers J, Sabb F, Schiffman J, Shah J, Silverstein S, Smesny S, Strauss G, Thompson J, Upthegrove R, Verma S, Wang J, Wolf D, Pasternak O, Bouix S, McGorry P, Kane J, Kahn R, Bearden C, Shenton M, Woods S, Nelson B, Stone W. Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample. Schizophrenia 2025, 11: 49. PMID: 40128256, PMCID: PMC11933323, DOI: 10.1038/s41537-025-00578-1.Peer-Reviewed Original ResearchCitationsAltmetricConceptsClinical high riskPenn Computerized Neurocognitive BatteryEstimated premorbid intelligenceComputerized Neurocognitive BatteryTransition to psychosisBiomarkers of schizophreniaPremorbid intelligenceCognitive batteryVerbal learningNeurocognitive batteryVerbal memoryWorking memorySchizophrenia ProgramCognitive domainsCurrent intelligenceVisual memorySensorimotor abilitiesProcessing speedCognitive AssessmentCognitive impairmentFollow-up timepointsEmotion recognitionSchizophreniaMemoryPsychosis
Clinical Trials
Current Trials
Song-making In a Group (SING)
HIC ID2000026376RoleSub InvestigatorPrimary Completion Date08/31/2024Recruiting ParticipantsSchizophrenia Spectrum Biomarkers Consortium (SSBC)
HIC ID2000029485RoleSub InvestigatorPrimary Completion Date12/31/2030Recruiting ParticipantsTesting a Computationally-Informed, Personalized Intervention for Hallucinations
HIC ID2000024774RolePrincipal InvestigatorPrimary Completion Date03/31/2024Recruiting ParticipantsGenderBothAge18 years - 65 yearsAMPA Receptor Components of the Anti-Depressant Ketamine Response
HIC ID2000021345RoleSub InvestigatorPrimary Completion Date06/30/2032Recruiting ParticipantsGenderBothAge18 years - 65 years
Academic Achievements & Community Involvement
Activities
activity American College of Neuropsychopharmacology (ACNP)
2022 - PresentProfessional OrganizationsAssociateDetailsAssociate Memberactivity Schizophrenia Research
11/01/2020 - 01/01/2022Journal ServiceGuest EditorDetailsGuest Editor, Special Issue on Computational Approaches to Understanding Psychosis
Honors
honor Young Physician-Scientist Award
01/26/2022National AwardAmerican Society for Clinical InvestigationDetailsUnited Stateshonor Carol and Eugene Ludwig Award for Early Career Research
12/08/2021National AwardLudwig Family FoundationDetailsUnited Stateshonor Second Prize, Yale Digital Pitchfest
12/01/2021Yale University AwardYale Office for Cooperative ResearchDetailsUnited Stateshonor Participant
07/18/2018National AwardCareer Development Institute for PsychiatryDetailsUnited Stateshonor New Investigator Award
07/18/2018National AwardAmerican Society of Clinical PsychopharmacologyDetailsUnited States
News
News
- May 27, 2025Source: Undark
When People Hear Voices, But Only When They Want To
- April 08, 2025
Understanding the Transition From Early to Chronic Psychosis
- April 07, 2025
Psychosis Symptoms Emerge in Surprising Pattern, Researchers Find
- December 20, 2024
Interdisciplinary Collaboration Yields Greater Impact
Get In Touch
Contacts
Academic Office Number